Date | Price Target | Rating | Analyst |
---|---|---|---|
11/13/2023 | $59.00 → $66.00 | Mkt Perform → Outperform | Keefe Bruyette |
9/15/2023 | $53.00 → $68.00 | Underperform → Buy | BofA Securities |
9/8/2023 | $51.00 | Sell | Goldman |
12/19/2022 | $63.00 → $60.00 | Outperform → Mkt Perform | Keefe Bruyette |
12/16/2022 | $55.00 | Equal Weight → Underweight | Wells Fargo |
1/14/2022 | $57.00 → $60.00 | Equal-Weight | Morgan Stanley |
1/4/2022 | $57.00 | Underweight → Equal-Weight | Wells Fargo |
11/19/2021 | $65.00 | Buy | Jefferies |
AXIS Capital Holdings Limited ("AXIS Capital" or "AXIS" or the "Company") (NYSE:AXS) today announced that Pranav Shroff has joined the Company as Head of Life Sciences in North America. Mr. Shroff will lead the development of a suite of specialty coverages in support of the life sciences industry, with an initial focus on Products Liability, Professional Liability, and Clinical Trials Liability. His responsibilities include executing on the underwriting strategy, cultivating relationships with our distribution partners in this specialty segment, and building a team to support this initiative. Bringing extensive underwriting experience and knowledge of life sciences, Mr. Shroff joins AXIS
AXIS Capital Holdings Limited ("AXIS Capital") (NYSE:AXS) today announced that W. Marston (Marty) Becker will succeed Henry B. Smith as non-executive Chair of its Board of Directors. Mr. Smith, who has served as Chair since May of 2020, has decided to transition from the Chair role and will continue to maintain a seat on the Board. The transition will take place in May of 2024, timed to the Company's Annual General Meeting. "There is no better individual to succeed me as Chair of the AXIS Board of Directors than Marty Becker. Over the past four years, the Company has benefitted enormously from Marty's wisdom, and deep understanding of the specialty property and casualty space," said Mr. S
AXIS Capital Holdings Limited ("AXIS Capital" or the "Company") (NYSE:AXS) announced today the hiring and appointment of Stephen Lord as Global Chief Information Officer (CIO) and Robert Barriero as Global Head of Strategic Sourcing and Corporate Real Estate. The hirings reflect the continued focus that the Company is placing on enhancing how it operates and goes to market through its "How We Work" program, which was introduced by President and CEO Vince Tizzio in 2023. As Global CIO, Mr. Lord will report directly to Mr. Tizzio and serve on the Company's Executive Committee. He joins AXIS from The Hartford where his most recent role was CIO, Global Specialty, Corporate Systems, HIMCO, and
B of A Securities analyst Joshua Shanker maintains Axis Capital Holdings (NYSE:AXS) with a Buy and raises the price target from $74 to $78.
Analysts' ratings for Axis Capital Holdings (NYSE:AXS) over the last quarter vary from bullish to bearish, as provided by 4 analysts. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 0 2 0 Last 30D 1 0 0 0 0 1M Ago 0 1 0 0 0 2M Ago 0 0 0 1 0 3M Ago 0 0 0 1 0 In the assessment of 12-month price targets, analysts unveil insights for Axis Capital Holdings, presenting an average target of $72.75, a high estimate of $86.00, and a low estimate of $57.00. Surpassing the previous average price targe
UBS analyst Brian Meredith maintains Axis Capital Holdings (NYSE:AXS) with a Buy and raises the price target from $82 to $85.
SC 13G/A - AXIS CAPITAL HOLDINGS LTD (0001214816) (Subject)
SC 13G/A - AXIS CAPITAL HOLDINGS LTD (0001214816) (Subject)
SC 13G/A - AXIS CAPITAL HOLDINGS LTD (0001214816) (Subject)
For the second quarter of 2024, the Company reports: Annualized return on average common equity ("ROACE") of 16.2% and annualized operating ROACE of 19.9% Improvement of 1.1 points in the combined ratio to 90.4% Book value per diluted common share of $59.29, an increase of $2.16, or 3.8%, compared to March 31, 2024 For the six months ended June 30, 2024, the Company reports: Net income available to common shareholders of $592 million, or $6.93 per diluted common share and operating income of $470 million, or $5.50 per diluted common share Annualized return on average common equity ("ROACE") of 24.1% and annualized operating ROACE of 19.1% Improvement of 0.4 points in th
AXIS Capital Holdings Limited ("AXIS Capital" or the "Company") (NYSE:AXS) today announced that it expects to release financial results for the second quarter ended June 30, 2024 on Tuesday, July 30, 2024 after the close of the financial markets. Vince Tizzio, President and Chief Executive Officer, and Peter Vogt, Chief Financial Officer, will host an investor teleconference, including a question and answer period, on Wednesday, July 31, 2024 at 8:30 AM ET to discuss the second quarter results as well as related matters. The teleconference can be accessed by dialing 1-877-883-0383 (U.S. callers), or 1-412-902-6506 (international callers), and entering the passcode 9099781 approximately
AXIS Capital Holdings Limited ("AXIS Capital" or the "Company") (NYSE:AXS) today announced that its Board of Directors has declared a quarterly dividend of $0.44 per common share payable on July 18, 2024 to shareholders of record at the close of business on June 28, 2024. In addition, the Board declared a dividend of $34.375 per Series E 5.50% preferred share (equivalent to $0.34375 per depositary share) payable on July 18, 2024 to shareholders of record at the close of business on June 28, 2024. AXIS Capital also announced that its Board of Directors approved a new share repurchase program, authorizing the Company to purchase up to an aggregate $300 million of the Company's common shar
AXIS Capital Holdings Limited ("AXIS Capital" or "AXIS" or the "Company") (NYSE:AXS) today announced that Pranav Shroff has joined the Company as Head of Life Sciences in North America. Mr. Shroff will lead the development of a suite of specialty coverages in support of the life sciences industry, with an initial focus on Products Liability, Professional Liability, and Clinical Trials Liability. His responsibilities include executing on the underwriting strategy, cultivating relationships with our distribution partners in this specialty segment, and building a team to support this initiative. Bringing extensive underwriting experience and knowledge of life sciences, Mr. Shroff joins AXIS
For the second quarter of 2024, the Company reports: Annualized return on average common equity ("ROACE") of 16.2% and annualized operating ROACE of 19.9% Improvement of 1.1 points in the combined ratio to 90.4% Book value per diluted common share of $59.29, an increase of $2.16, or 3.8%, compared to March 31, 2024 For the six months ended June 30, 2024, the Company reports: Net income available to common shareholders of $592 million, or $6.93 per diluted common share and operating income of $470 million, or $5.50 per diluted common share Annualized return on average common equity ("ROACE") of 24.1% and annualized operating ROACE of 19.1% Improvement of 0.4 points in th
AXIS Capital Holdings Limited ("AXIS Capital" or the "Company") (NYSE:AXS) today announced that it expects to release financial results for the second quarter ended June 30, 2024 on Tuesday, July 30, 2024 after the close of the financial markets. Vince Tizzio, President and Chief Executive Officer, and Peter Vogt, Chief Financial Officer, will host an investor teleconference, including a question and answer period, on Wednesday, July 31, 2024 at 8:30 AM ET to discuss the second quarter results as well as related matters. The teleconference can be accessed by dialing 1-877-883-0383 (U.S. callers), or 1-412-902-6506 (international callers), and entering the passcode 9099781 approximately
Keefe Bruyette upgraded AXIS Capital from Mkt Perform to Outperform and set a new price target of $66.00 from $59.00 previously
BofA Securities upgraded AXIS Capital from Underperform to Buy and set a new price target of $68.00 from $53.00 previously
Goldman initiated coverage of AXIS Capital with a rating of Sell and set a new price target of $51.00
4 - AXIS CAPITAL HOLDINGS LTD (0001214816) (Issuer)
4 - AXIS CAPITAL HOLDINGS LTD (0001214816) (Issuer)
4 - AXIS CAPITAL HOLDINGS LTD (0001214816) (Issuer)
8-K - AXIS CAPITAL HOLDINGS LTD (0001214816) (Filer)
8-K - AXIS CAPITAL HOLDINGS LTD (0001214816) (Filer)
13F-HR - AXIS CAPITAL HOLDINGS LTD (0001214816) (Filer)
4 - AXIS CAPITAL HOLDINGS LTD (0001214816) (Issuer)
4 - AXIS CAPITAL HOLDINGS LTD (0001214816) (Issuer)
4 - AXIS CAPITAL HOLDINGS LTD (0001214816) (Issuer)